AwesomeCapital

Walgreens Boots Alliance FQ3 earnings down 24%, ytd cash flow down 41%

Walgreens Boots Alliance (NASDAQ:WBA) fiscal Q3 results ($M): Sales: 34,591 (+0.7%).

Net income: 1,025 (-23.6%); non-GAAP net income: 1,338 (-12.1%); EPS: 1.13 (-16.3%); non-GAAP EPS: 1.47 (-3.9%).

Cash flow ops (9 mo.): 3,215 (-41.0%).

Q3 cash flow ops was $2B.

Retail pharmacy USA sales up 2.3% to $26.5B. Pharmacy sales up 4.3%. Prescriptions up 1.9% to 290.7M.

Retail sales down 2.9%.

Operating income down 20.6%.

Fiscal 2019 guidance: Non-GAAP EPS: down $0.06.

Shares are up 2% premarket.

https://seekingalpha.com/news/3474224-walgreens-boots-alliance-fq3-earnings-24-percent-ytd-cash-flow-41-percent

Aridis Pharma’s AR-501 an Orphan Drug in U.S. for CF lung infection

The FDA has granted Orphan Drug Designation (ODD) to Aridis Pharmaceuticals’ (NASDAQ:ARDS) AR-501, an inhaled formulation of gallium citrate for treatment of lung infection in patients with cystic fibrosis (CF).

Among the benefits of Orphan Drug status is a seven-year period of market exclusivity for the indication, if approved.

https://seekingalpha.com/news/3474181-aridis-pharmas-arminus-501-orphan-drug-u-s-cf-lung-infection

AstraZeneca’s Imfinzi extends survival in first-line lung cancer

Results from a Phase 3 clinical trial, CASPIAN, evaluating AstraZeneca’s (NYSE:AZN) Imfinzi (durvalumab), combined with platinum-based chemo compared to chemo alone or combined with tremelimumab and chemo versus chemo alone, for the treatment of small cell lung cancer in a first-line setting showed a statistically significant improvement in overall survival (OS).

Detailed data will be submitted for presentation at a future medical conference.

https://seekingalpha.com/news/3474192-astrazenecas-imfinzi-extends-survival-first-line-lung-cancer